Agios Pharmaceuticals said it is ending development of tebapivat, its next-generation pyruvate kinase (PK) activator for sickle cell disease, after a Phase 2 study failed to show a differentiated profile needed to continue. The company said tebapivat did not meet the threshold for further development and framed the move as a portfolio reset. Tebapivat had been positioned as a differentiating variant of Agios’ already-approved mitapivat franchise in blood disorders. With investors watching differentiation versus Novo Nordisk’s enzyme activator program after positive Phase 3 results, Agios’ decision underscores how high the bar remains for efficacy, safety, and market positioning in sickle cell. The development follows other recent sickle cell program cutbacks across the industry amid safety, regulatory, and clinical durability challenges. Agios also disclosed earlier mixed late-stage mitapivat results against sickle cell, adding to pressure on the class. Agios shares were reported down in mid-morning trading following the announcement, reflecting how quickly mid-stage outcomes can reprice expectations for genetically and biologically complex indications like sickle cell.